Daphnetin

PreclinicalSmall molecule

FFirst People's Hospital of Shenyang

Daphnetin is one of 48 small molecule programs targeting Cognitive impairment. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

Cognitive ImpairmentPreclinical

Active, not recruiting

Competition

Competitive Landscape

279 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

Actos

Takeda

Phase 3

3 2

Farxiga

AstraZeneca

Phase 3

1 3

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 4

Provigil

NNuvo Research GmbH

Phase 3

1 5

Xarelto

WWim Janssens

Phase 3

1 6

Viagra

VViatris Specialty LLC

Phase 3

1 7

Donepezil Hydrochloride

Eisai

Phase 3

3 8

Statins

Sanofi

Phase 3

1 9

Galantamine Hydrobromide

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

4 10

Karx-EC

Bristol-Myers Squibb

Phase 3

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Surgery1 trial

Daphnetin Capsules for Lower Limb Lymphoedema Following Gynaecological Surgery

Recruiting·TThe First Hospital of Jilin University·Phase 4·NCT06329167·100 enrolled

Cognitive impairment1 trial

Daphnetin Capsule In the Treatment of VaScular COgnitive Impairment Without Dementia

Recruiting·FFirst People's Hospital of Shenyang·N/A·NCT06507488·206 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Daphnetin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Daphnetin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Daphnetin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First People's Hospital of Shenyang company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: FFirst People's Hospital of Shenyang

Daphnetin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Surgery1 trial

Cognitive impairment1 trial

References

Drug Info

Quick Facts

Related News